Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study.

Pirnay JP, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, Glonti T, Spiessens A, Vanden Berghe E, Green S, Wagemans J, Lood C, Schrevens E, Chanishvili N, Kutateladze M, de Jode M, Ceyssens PJ, Draye JP, Verbeken G, De Vos D, Rose T, Onsea J, Van Nieuwenhuyse B, Bacteriophage Therapy Providers, Bacteriophage Donors, Soentjens P, Lavigne R, Merabishvili M. · 2024

Read Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. by Pirnay JP, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, Glonti T, Spiessens A, Vanden Berghe E, Green S, Wagemans J, Lood C, Schrevens E, Chanishvili N, Kutateladze M, de Jode M, Ceyssens PJ, Draye JP, Verbeken G, De Vos D, Rose T, Onsea J, Van Nieuwenhuyse B, Bacteriophage Therapy Providers, Bacteriophage Donors, Soentjens P, Lavigne R, Merabishvili M. (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc11153159.txt.

Introduction

Pirnay and a large multinational team report outcomes for 100 personalised virus treatments of stubborn infections in this 2024 study. Bacteriophages are viruses that infect and kill bacteria. Personalised phage therapy picks phages matched to a patient's own germ. Trials of off-the-shelf phage products had disappointed, so the team reviewed tailored cases instead.

The 100 cases ran from 2008 to 2022 across 35 hospitals in 12 countries, coordinated by a Belgian consortium. Lung, skin, and bone infections were most common. Treatment used 26 phages and six defined cocktails, sometimes pre-adapted to the target germ. Clinical improvement was reported for 77.2 percent of infections, and the target germ was cleared in 61.3 percent. Skipping antibiotics alongside phages cut the odds of clearance sharply, their analysis found.

Catalog record

CREATORPirnay JP, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, Glonti T, Spiessens A, Vanden Berghe E, Green S, Wagemans J, Lood C, Schrevens E, Chanishvili N, Kutateladze M, de Jode M, Ceyssens PJ, Draye JP, Verbeken G, De Vos D, Rose T, Onsea J, Van Nieuwenhuyse B, Bacteriophage Therapy Providers, Bacteriophage Donors, Soentjens P, Lavigne R, Merabishvili M.
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE104 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11153159

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study By Jean-Paul Pirnay, Sarah Djebara, Griet Steurs, Johann Griselain, Christel Cochez, Steven De Soir, Tea Glonti, An Spiessens, Emily Vanden Berghe, Sabrina Green, Jeroen Wagemans, Cédric Lood Published in: Nature Microbiology DOI: 10.1038/s41564-024-01705-x ABSTRACT Abstract In contrast to the many reports of successful real-world cases of personalized bacteriophage therapy (BT), randomized controlled trials of non-personalized bacteriophage products have not produced the expected results. Here we present the outcomes of a retrospective observational analysis of the first 100 consecutive cases of personalized BT of difficult-to-treat infections facilitated by a Belgian consortium in 35 hospitals, 29 cities and 12 countries during the period from 1 January 2008 to 30 April 2022. We assessed how often personalized BT produced a positive clinical outcome (general efficacy) and performed a regression analysis to identify functional relationships. The most common indications were lower respiratory tract, skin and soft tissue, and bone infections, and involved combinations of 26 bacteriophages and 6 defined bacteriophage cocktails, individually selected and sometimes pre-adapted to target the causative bacterial pathogens. Clinical improvement and eradication of the targeted bacteria were reported for 77.2% and 61.3% of infections, respectively. In our dataset of 100 cases, eradication was 70% less probable when no concomitant antibiotics were used (odds ratio = 0.3; 95% confidence interval = 0.127–0.749). In vivo selection of bacteriophage resistance and in vitro bacteriophage–antibiotic synergy were documented in 43.8% (7/16 patients) and 90% (9/10) of evaluated patients, respectively. We observed a combination of antibiotic re-sensitization and reduced virulence in bacteriophage-resistant bacterial isolates that emerged during BT. Bacteriophage immune neutralization was observed in 38.5% (5/13) of screened patients. Fifteen adverse events were reported, including seven non-serious adverse drug reactions suspected to be linked to BT. While our analysis is limited by the uncontrolled nature of these data, it indicates that BT can be effective in combination with antibiotics and can inform the design of future controlled clinical trials. BT100 study, ClinicalTrials.gov registration: NCT05498363. Subject terms: Bacterial infection, Bacteriophages, Bacterial genetics, Antimicrobial resistance MAIN Antimicrobial resistance (AMR) is a prominent global health threat with an estimated 1.27 million attributable deaths in 20191 and there is an urgent need to seek alternative antimicrobial strategies. Bacteriophage therapy (BT), the use of bacteriophages—the viruses of bacteria—to treat bacterial infections, was first applied by Félix d’Hérelle in 19192, and further developed and applied in the former Soviet Union. A recent systematic review confirmed that BT can generally be considered as safe, with a low incidence of adverse events, and could be a promising strategy against AMR3. However, high-quality trials are required to make useful predictions on the outcome of bacteriophage treatments. A number of companies are currently attempting to develop and market defined broad-spectrum BT products in compliance with contemporary requirements, which involves good manufacturing practices (GMP) certification, preclinical research (toxicity and pharmacology) and conducting randomized controlled trials (RCTs). However, the handful of bacteriophage RCTs that have been performed so far have not brought the expected results in terms of effectiveness4. A commonly reported reason for these disappointing results is the use of invariable one-size-fits-all bacteriophage products4. In contrast, an increasing number of successful BT cases are reported in the scientific literature3. Irrespective of an obvious positive-result publication bias, most of these successful cases used tailored bacteriophage products. In addition, these personalized bacteriophage preparations, which were shown to target the infecting bacteria in vitro before their clinical application, were often used in combination with antibiotics. When appropriate, bacteriophage preparations were adapted to counter bacterial resistance that had emerged against the applied bacteriophages during BT5, or bacteriophages were pre-adapted (‘trained’)6 or engineered7 to be more effective. Here we report the retrospective, observational analysis of the first 100 consecutive BT cases of difficult-to-treat infections, enabled by a Belgian consortium. Because all BT cases were included in this study, not only successful, interesting, or challenging cases, we were able to (1) evaluate how often personalized BT produced a positive clinical outcome (general efficacy) and (2) identify functional relationships that are general in all cases. Considering the relatively high number of combined categorical and numerical variables in the analysed data, the majority of patients were unique cases in most of the variables. As a result, on this dataset, no inferential statistics could be applied because these data were neither a random nor a representative sample of a population of BT-treated patients. As such, any data analysis can only be interpreted as information pertaining to the analysed patient population. Nevertheless, the knowledge gained from these cases is likely to help physicians to select effective treatment protocols and design future clinical trials. RESULTS Patients, bacterial infections and bacteriophage therapy A Belgian BT consortium, consisting of the Queen Astrid Military Hospital (QAMH), KU Leuven and Sciensano (formerly known as the Scientific Institute of Public Health), facilitated BT in about 140 difficult-to-treat infections in patients in Belgium and abroad (as of July 2023), not taking into account the patients treated in the context of prospective clinical trials. The selection of patients was largely based on clinical need, regulatory approval and the availability of well-characterized bacteriophages targeting the infecting bacteria (Extended Data Fig. 1). Personalized bacteriophage preparations were produced at the QAMH in accordance with the rules in force in the territory at the time of their use in clinical practice. Of note, most selected cases concerned personalized BT as salvage therapy after standard antibiotic treatments had failed. Quality and safety of the bacteriophage preparations were verified by Sciensano according to the specifications of the Belgian bacteriophage active pharmaceutical ingredient (API) monograph8, that is, the genomic analysis of the bacteriophage and its bacterial production host (with an emphasis on safety), and the determination of lytic activity (titre), pH, bioburden (total viable aerobic count), bacterial endotoxin level and genome sequence (identity and purity) of each bacteriophage API batch. The BT protocols that were suggested to the treating physicians were based on the experiences of the George Eliava Institute of Bacteriophages, Microbiology and Virology (Eliava Institute) in Tbilisi, Georgia (personal communications), and on the application instructions of the Ministries of Health and of Medical and Microbiology Industry of the former Union of Soviet Socialist Republics (USSR)9–11. [Figure: The Phage Therapy Coordination Centre’s patient selection process for bacteriophage therapy.] During the study period (1 January 2008 to 30 April 2022), 1,066 BT requests were submitted to the QAMH. These requests resulted in 100 BT cases (9.4%). Two hundred and sixty BT requests addressed to the QAMH between April 2013 and April 2018 were analysed in detail12. Only 15 (5.8%) of these 260 requests resulted in actual BT. Two hundred and forty-five requests were rejected for diverse reasons: 70 applicants (26.9%) did not respond to requests for additional information; 124 requests (47.7%) concerned bacterial species against which no bacteriophages were available at the QAMH; for 46 requests (17.7%), other therapeutic options were considered more opportune; and in 5 cases (1.9%) the available bacteriophages did not target the patients’ infecting bacterial strains. Rejected applications were usually referred to BT centres abroad. We consider these percentages as representative of the present patient cohort, minding an increase in the percentage of requests that resulted in BT (9.4% versus 5.8%), which is

Read the complete text